Rolapitant Is a Reversible Inhibitor of CYP2D6 [PDF]
Drug Metabolism and Disposition, 2019 Rolapitant [(Varubi), 5S,8S)-8-[[(1R)-1-[3,5 bis(trifluoromethyl phenyl]ethoxy]methyl]-8-phenyl-1,7-diazaspiro[4.5]decan-2-one] is a high-affinity NK1 receptor antagonist that was approved in September 2015 as a treatment for nausea and vomiting caused by chemotherapy.
Sarah M. Glass +5 more
openaire +2 more sources
Tamoxifen and CYP2D6: A Contradiction of Data [PDF]
The Oncologist, 2012 Abstract Learning Objectives: After completing this course, the reader will be able to: Describe the significant heterogeneity among the published studies on the link between CYP2D6 genotype and tamoxifen treatment efficacy.Explain the role of CYP2D6 metabolism in the conversion of tamoxifen to its ...
Howard L. McLeod +2 more
openaire +3 more sources
Identification of novel CYP2D7-2D6 hybrids: non-functional and functional variants
Frontiers in Pharmacology, 2010 Polymorphic expression of CYP2D6 contributes to the wide range of activity observed for this clinically important drug metabolizing enzyme. In this report we describe novel CYP2D7/2D6 hybrid genes encoding non-functional and functional CYP2D6 protein and
Andrea Gaedigk +6 more
doaj +1 more source
Clinical application of high throughput molecular screening techniques for pharmacogenomics. [PDF]
, 2011 Genetic analysis is one of the fastest-growing areas of clinical diagnostics. Fortunately, as our knowledge of clinically relevant genetic variants rapidly expands, so does our ability to detect these variants in patient samples.
Schrijver, Iris, Wiita, Arun P
core +1 more source
A novel simple method for determining CYP2D6 gene copy number and identifying allele(s) with duplication/multiplication. [PDF]
PLoS ONE, 2015 BACKGROUND:Cytochrome P450 2D6 (CYP2D6) gene duplication and multiplication can result in ultrarapid drug metabolism and therapeutic failure or excessive response in patients.
Taimour Langaee +4 more
doaj +1 more source
Toward a clinical practice guide in pharmacogenomics testing for functional polymorphisms of drug-metabolizing enzymes. Gene/drug pairs and barriers perceived in Spain [PDF]
, 2012 The development of clinica lpractice recommendations or guidelines for the clinical use of biomarkers is an issue of great importance withr regard to adverse drug reactions.The poten-tial of pharmacogenomicbiomarkers has been extensively investigated in
Abad Santos, Francisco +18 more
core +4 more sources
Anemarsaponin BII inhibits the activity of CYP3A4, 2D6, and 2E1 with human liver microsomes
Pharmaceutical Biology, 2020 Context Anemarsaponin BII is one of the most active saponins isolated from Anemarrhena asphodeloides Bunge (Asparagaceae), a commonly used Chinese traditional paediatric medicine.
Mingwei Wang +4 more
doaj +1 more source
Current medical treatment of estrogen receptor-positive breast cancer [PDF]
, 2015 Approximately 80% of breast cancers (BC) are estrogen receptor (ER)-positive and thus endocrine therapy (ET) should be considered complementary to surgery in the majority of patients.
Basso, S. M. M. +2 more
core +1 more source
Sex Differences in Associations Between CYP2D6 Phenotypes and Response to Opioid Analgesics
Pharmacogenomics and Personalized Medicine, 2020 Guilherme S Lopes,1,2 Suzette J Bielinski,2 Ann M Moyer,3 John Logan Black III,3 Debra J Jacobson,1 Ruoxiang Jiang,1 Nicholas B Larson,1 Jennifer L St Sauver2 1Division of Biomedical Statistics and Informatics, Department of Health Sciences Research ...
Lopes GS +7 more
doaj
CYP2D6 Substrate Dispensing Among Patients Dispensed Mirabegron: An Administrative Claims Analysis
Drugs - Real World Outcomes, 2022 Background Overactive bladder (OAB) is characterized by the presence of bothersome urinary symptoms. Pharmacologic treatment options for OAB include anticholinergics and β3-adrenergic agonists.
Mary E. Ritchey +7 more
doaj +1 more source